Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors ...

Biogen (NASDAQ:BIIB – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $220.00 to ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

On Monday, Biogen Inc (BIIB) stock saw a decline, ending the day at $173.52 which represents a decrease of $-0.27 or -0.16% from the prior close of $173.79. The stock opened at $173.22 and touched a ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Needham analyst Ami Fadia has maintained their bullish stance on BIIB stock, giving a Buy rating yesterday. Ami Fadia has given her Buy rating ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB.

Biogen partners with Neomorph to develop molecular glue degraders for Alzheimer's and other diseases, offering up to $1.45B in payments.